Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
HNO ; 64(7): 501-7, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27357174

ABSTRACT

INTRODUCTION: For the treatment of head and neck squamous cell carcinoma (HNSCC), there are currently no official standard of care guidelines in German-speaking countries, with the exception of oral cavity cancer. In order to learn about the applied treatment modalities in the clinical routine, we conducted a web-based survey to evaluate the local standards of palliative and curative treatment of HNSCC. This article focuses on the curative treatment options and organ preservation strategies. MATERIALS AND METHODS: The survey consisted of a web-based questionnaire that was performed between November 2013 and July 2014. The questionnaire included ten multiple-choice questions and four open questions in the section about curative treatment. RESULTS: Altogether, 62 of the 204 addressed centers participated in the survey. For primary chemoradiation (CRT), most centers used a platinum-based chemotherapy (52/54, 96.3 %). Induction chemotherapy (ICT) was offered in 37 of the 62 centers (60 %). In oral cavity cancer, CRT and ICT were used in 37.5 and 4.3 % of the cases, respectively. In oropharyngeal cancer, CRT and ICT were applied in 44.5 and 10.3 % of cases, respectively. For hypopharyngeal cancer, 44.8 % of the patients received CRT and 11.8 % received ICT, while for laryngeal cancer 35.9 % received CRT and 9.4 % underwent ICT. CONCLUSION: Our data showed that a variety of treatments are used for HNSCC within German-speaking countries. Many centers offer ICT. The majority of the hospitals uses platinum-based therapy as a conservative first-line option in their organ preservation protocols.


Subject(s)
Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/therapy , Chemoradiotherapy/statistics & numerical data , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/therapy , Induction Chemotherapy/statistics & numerical data , Organ Sparing Treatments/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Adult , Aged , Antineoplastic Agents/toxicity , Austria/epidemiology , Carcinoma, Squamous Cell/diagnosis , Germany/epidemiology , Head and Neck Neoplasms/diagnosis , Health Care Surveys , Humans , Middle Aged , Prevalence , Squamous Cell Carcinoma of Head and Neck , Switzerland/epidemiology
2.
HNO ; 64(7): 487-93, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27299894

ABSTRACT

BACKGROUND: The EXTREME (Erbitux in First-Line Treatment of Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma) protocol is generally considered the gold standard in palliative first-line treatment. However, there is some disagreement about its effectivity, toxicity, and applicability in daily clinical routine. The purpose of this cross-sectional survey was to describe the palliative treatment offered in German-speaking countries. METHODS: From November 2013 to July 2014, 204 departments of otorhinolaryngology (ORL) in Germany, Austria, and the German-speaking parts of Switzerland were contacted and invited to take part in a web-based survey on the treatment of HNSCC. RESULTS: In all, 62 of 204 treatment centers (30.4 %) participated in the survey. Of these, 58 departments offered palliative systemic therapy to their patients; 19 of 58 (32.8 %) treated patients undergoing palliative chemotherapy in their own ORL departments, while 40 of 58 (69 %) upheld a cooperation with medical oncologists in the same hospital and 24 of 58 (41.4 %) with medical oncologic practices. Many of these treatment centers offered multiple locations for treatment. Of the 58 departments, 56 provided an institutional standard for first-line palliative treatment, 13 for second-line, and two for third-line treatment. In 42 of 58 departments the EXTREME protocol was the institutional standard of care for first-line treatment. Moreover, 12 of 58 departments mentioned an individual protocol and two of 58 the inclusion in clinical trials as their local standard. The assessment of patients who could be treated with the first-line standard ranged from 0 to 95 % with a mean of 44.5 %. CONCLUSION: Palliative systemic therapy seems to be well standardized for first-line treatment, whereas there is little standardization in second- and third-line treatments. A large variation was found regarding the estimate of the applicability of the institutional standard. Reasons for this could be the physicians' individual experience as well as the varying assessment regarding the toxicity of palliative systemic therapy.


Subject(s)
Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/therapy , Guideline Adherence/statistics & numerical data , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/therapy , Palliative Care/statistics & numerical data , Palliative Care/standards , Practice Guidelines as Topic , Adult , Aged , Austria/epidemiology , Carcinoma, Squamous Cell/diagnosis , Female , Germany/epidemiology , Guideline Adherence/standards , Head and Neck Neoplasms/diagnosis , Health Care Surveys , Humans , Male , Medical Oncology/standards , Middle Aged , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/statistics & numerical data , Prevalence , Squamous Cell Carcinoma of Head and Neck , Switzerland/epidemiology
3.
HNO ; 64(7): 494-500, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27286727

ABSTRACT

BACKGROUND: The treatment of head and neck squamous cell carcinoma (HNSCC) is highly complex and requires a multimodal approach. However, guidelines for the treatment of most forms of HNSCC do not exist in German-speaking countries with the exception of oral cavity cancer. The aim of this cross-sectional study was to describe the current treatment landscape and infrastructure in German-speaking countries. METHODS: From November 2013 to July 2014, 204 departments of otorhinolaryngology (ORL) in Germany, Austria, and the German-speaking part of Switzerland were contacted and invited to take part in a web-based survey on the treatment of HNSCC. In order to cover the study in its entirety, we published three consecutive papers of which this paper is the first. RESULTS: In all, 62 treatment centers (30.4 %) participated in the survey. These centers included 21 university hospitals, 16 certified cancer centers, and 35 large centers, which diagnose at least 75 HNSCC patients annually. In 91.9 % of all cases, there were outpatient consultation hours (that were monodisciplinary in 61.4 %). A multidisciplinary tumor board was existent in 98.4 % of the cases. Of 62 ORL departments, 50 had a hospital cancer registry, 41 of 62 conducted oncological studies, and 35 of 62 assessed their patients' quality of life. CONCLUSION: The infrastructure of the treatment for HNSCC can be considered mostly well-developed and supports interdisciplinary cooperation. Potential improvements can be made regarding the standardization of tumor boards, the participation in clinical trials, and the availability of cancer registries and the data gathered therein.


Subject(s)
Cancer Care Facilities/supply & distribution , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/therapy , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/therapy , Medical Oncology/statistics & numerical data , Patient Care Team/statistics & numerical data , Referral and Consultation/statistics & numerical data , Austria/epidemiology , Carcinoma, Squamous Cell/diagnosis , Cross-Sectional Studies , Germany/epidemiology , Head and Neck Neoplasms/diagnosis , Health Care Surveys , Humans , Prevalence , Squamous Cell Carcinoma of Head and Neck , Switzerland/epidemiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...